Your activity: 2 p.v.
< Back

Trimodality studies in pleural malignant pleural pneumonectomy

Trimodality studies in pleural malignant pleural pneumonectomy
Ref n Chemotherapy RR
(percent)		 EPP done
(percent)		 Mortality
(percent)		 Completed trimodal
(percent)		 OS (ITT) months OS: Subsets months PFS months
Weder[1] 19 32 84 0 68 23 NR CT + EPP: 16.5
Weder[2] 61 NR 74 2.2 59 19.8 CT + EPP: 23 CT + EPP: 13.5
Rea[3] 21 33 81 0 71 25.5 27.5 CT + EPP: 16.3
Flores[4] 21 26 42 0 42 19 CT + EPP + RT: 33.5 NR
Opitz[5] 63 32 – 3.2 – NR NR NR
Buduhan[6] 55 NR 84 4.3 69 NR CT + EPP: 24
TMT: 25		 NR
de Perrot[7] 60 NR 75 6.7 50 14 NR NR
Krug[8] 77 32 70 4 52 16.8 CT + EPP: 21.9
TMT: 29.1		 ITT: 10.1
CT + EPP: 18.3
Van Schil[9] 58 43 72 6.5 65 18.4 TMT: 33 ITT: 13.9
Rea[10] 54 29 83 NR 41 15.5 NR ITT PFS: 8.6
Bille[11] 25 NR 88 4 71 12.8 NR NR
Okada[12] 27 NR 100 3.7 63 13 23 (chemoRT after EPP) NR
RR: response rate; EPP: extrapleural pneumonectomy; OS: overall survival; PFS: progression free survival; CT: chemotherapy; TMT: trimodality therapy; ITT: intent to treat; NR: not recorded.
References:
  1. Weder W, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22(17):3451, 2004.
  2. Weder W, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18(7):1196, 2007.
  3. Rea F, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer 57(1):89, 2007.
  4. Flores RM, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1(4):289, 2006.
  5. Opitz I, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(4):579, 2006.
  6. Buduhan G, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 88(3):870, 2009.
  7. de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413, 2009.
  8. Krug LM, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007, 2009.
  9. Van Schil PE, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36(6):1362, 2010.
  10. Pasello G, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res 32(12):5393, 2012.
  11. Bille A, et al: Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg 60(5):289, 2012.
  12. Okada K: Trimodality Therapy With Extrapleural Pneumonectomy, Radiation Therapy, And Chemotherapy For Malignant Pleural Mesothelioma. 11th International Conference of the International Mesothelioma Interest Group. 2012.
Graphic 88466 Version 3.0